3M announced today that it completed the spinoff of its Solventum healthcare business as a standalone company. Following the completion of the spinoff, Solventum is now listed on the New York Stock Exchange under the “SOLV” ticker. The 3M board approved the spinoff in March, confirming the effective date for today, April 1. The St. […]
Wall Street Beat
Axonics stockholders approve Boston Scientific acquisition
Axonics (Nasdaq:AXNX) announced that its stockholders voted to adopt its $3.7 billion merger agreement with Boston Scientific . Boston Scientific announced its intent to buy Axonics on Jan. 8. Irvine, California-based Axonics develops neuromodulation systems for treating urinary and bowel dysfunction. Its fourth-generation R20 rechargeable sacral neuromodulation (SNM) system received FDA approval around a year ago. […]
3M board approves Solventum healthcare spinoff
3M announced last week that its board of directors approved the planned spinoff of Solventum, its Health Care business. Board approval further solidifies the company’s previously announced intent to spin Solventum into a standalone company on April 1. The St. Paul, Minnesota–based manufacturing giant first announced plans to spin off its Health Care unit in […]
Myomo has a strong outlook for 2024 with new Medicare coverage
Myomo (NYSE:MYO) shares took a hit today on fourth-quarter results that came up short of the consensus forecast. Shares of MYO fell 10% to $3.16 apiece in mid-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — ticked up 0.5%. The Boston-based wearable exoskeleton maker posted […]
Orthofix beats Street in Q4, analysts see positive signs for future
Orthofix Medical are up today on fourth-quarter results that topped the consensus forecast. The Lewisville, Texas–based company posted losses of $22.2 million in the quarter. That equals 59¢ per share on sales of $200.4 million for the three months ended Dec. 31, 2023. The company’s bottom line dipped by more than $15 million further into […]
Vicarious Surgical still expects to submit surgical robot to FDA in 2026
Vicarious Surgical (NYSE:RBOT) management offered an update on the development timeline of its surgical robot as part of its fourth-quarter earnings. Previous expectations earmarked mid-2024 for first-in-human trials and fiscal 2025 for de novo clearance submission. However, CEO Adam Sachs pushed V1.0’s timeline back in November 2023. The company outlined plans for a build and […]
Stereotaxis submits Magic ablation catheter for U.S., European approval
Stereotaxis (NYSE:STXS) announced that it submitted its Magic ablation catheter for both European and U.S. regulatory approval. The company said its FDA and CE mark submissions follow successful clinical results in an ongoing trial. Last month, Stereotaxis announced the first Magic treatments in the European trial supporting its submissions. According to a news release, the […]
iRhythm proposes $450M offering
iRhythm announced today that it intends to offer $450 million in convertible senior notes. San Francisco–based iRhythm plans to offer the notes — due 2029 — to qualified institutional buyers. It intends to grant initial purchasers a 13-day option to buy up to an additional $67.5 million in notes. The notes will be senior, unsecured […]
FDA submission for 365-day CGM from Senseonics is ‘imminent’
Senseonics (NYSE:SENS) shares dipped after hours on fourth-quarter results that came in ahead of the consensus forecast. The company also reported an “imminent” submission of its latest, longest-lasting continuous glucose monitoring (CGM) technology. Shares of SENS fell 3.5% to 69¢ apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of […]
Masimo stock dips despite Street-beating Q4
Masimo shares fell slightly despite fourth-quarter results that came in ahead of the consensus forecast. Shares of MASI dipped 2.6% at $126.76 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — fell 0.3%. The Irvine, California–based patient monitoring technology developer posted profits of […]
Smith+Nephew sales are up 7% as 12-point plan progresses
Smith+Nephew shares dipped today on fourth-quarter results that included nearly 7% sales growth year-over-year. Shares of SNN fell 2% to $27.97 apiece in late-afternoon trading. The London-based orthopedic giant posted sales of $1.458 million in the quarter. That marked 6.8% growth compared to the same period a year ago. Smith+Nephew says it continues to make […]